Fulcrum Therapeutics Inc is a biopharmaceutical company focused on developing innovative therapies for serious genetic diseases
The company leverages its proprietary drug discovery platform to address the underlying causes of these conditions, particularly in diseases caused by gene mutations and epigenetic factors. By targeting specific pathways and mechanisms, Fulcrum aims to create treatments that significantly improve the quality of life for patients affected by these challenging disorders. Its commitment to scientific innovation and collaboration with the medical community drives the advancement of potential therapies from preclinical stages through clinical development.
MyoKardia, a Bristol Myers unit, is terminating its agreement with Fulcrum Therapeutics, ending a cardiomyopathy research deal set to expire in June 2025.
The US market is yet to commence its session on Wednesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
What has Wall Street been buzzing about this week? Here are the top 5 buy calls and the top 5 sell calls made by Wall Street's best analysts during the trading week of Sept. 9-13, 2024.
Fulcrum Therapeutics stock drops after Phase 3 REACH trial of losmapimod flops in Facioscapulohumeral Muscular Dystrophy. The company consider suspending the program.
BofA Securities upgraded Fulcrum Therapeutics ahead of its phase 3 losmapimod results for Facioscapulohumeral muscular dystrophy, boosting the price target from $5 to $10 due to increased confidence in the study's success.
